Attached files
| file | filename |
|---|---|
| 10-K - 10-K - Arbutus Biopharma Corp | arbutus10k2019.htm |
| EX-32.2 - EXHIBIT 32.2 - Arbutus Biopharma Corp | exhibit322_soxcertcfo2019.htm |
| EX-32.1 - EXHIBIT 32.1 - Arbutus Biopharma Corp | exhibit321_soxcertceo2019.htm |
| EX-31.2 - EXHIBIT 31.2 - Arbutus Biopharma Corp | exhibit312_10-kcertcfo2019.htm |
| EX-31.1 - EXHIBIT 31.1 - Arbutus Biopharma Corp | exhibit311_10-kcertceo2019.htm |
| EX-23.1 - EXHIBIT 23.1 - Arbutus Biopharma Corp | exhibit231_kpmgconsent2019.htm |
| EX-21.1 - EXHIBIT 21.1 - Arbutus Biopharma Corp | exhibit211_listingofsubsid.htm |
| EX-4.2 - EXHIBIT 4.2 - Arbutus Biopharma Corp | exhibit42descriptionofsecu.htm |
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
1) | Registration Statement (Form S-3 No. No. 333-235674) pertaining to the offering, issuance and sale of up to $150,000,000 of common shares, preferred shares, warrants, debt securities and units of Arbutus Biopharma Corporation, |
2) | Registration Statement (Form S-8 No. 333-233192) pertaining to the Inducement Plan of Arbutus Biopharma Corporation, |
3) | Registration Statement (Form S-8 No. 333-228919) pertaining to the 2011 Omnibus Share Compensation Plan, |
4) | Registration Statement (Form S-8 No. 333-212115) pertaining to the 2016 Omnibus Share and Incentive Plan, |
5) | Registration Statement (Form S-8 No. 333‑202762) pertaining to the OnCore Biopharma, Inc. 2014 Equity Incentive Plan, and |
6) | Registration Statement (Form S-8 No. 333-186185) pertaining to the Tekmira 2011 Omnibus Share |
Compensation Plan, the Tekmira Share Option Plan and the Protiva 2000 Incentive Stock Option Plan
of our reports dated March 5, 2020, with respect to the consolidated financial statements of Arbutus Biopharma Corporation and the effectiveness of internal control over financial reporting of Arbutus Biopharma Corporation included in this Annual Report (Form 10-K) of Arbutus Biopharma Corporation for the year ended December 31, 2019.
/s/ Ernst Young LLP
Philadelphia, Pennsylvania
March 5, 2020